Casaasdas

A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).

Por um escritor misterioso
Last updated 27 dezembro 2024
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study - Irene E. van der Horst-Bruinsma, Rianne E.
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Oscar IRVIN-SELLERS, Medigene AG
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex, Arthritis Research & Therapy
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial - The Lancet
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study - Pavelka - 2020 - ACR Open Rheumatology - Wiley Online Library
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Mean (A) ASDAS and (B) BASDAI up to Week 48. Safety Set (N=89).
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. - Abstract - Europe PMC
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Poster Abstract Presentation Abstracts - 2023 - International Journal of Rheumatic Diseases - Wiley Online Library
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
TNF Inhibitor Therapy, Ankylosing Spondylitis
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
IJMS, Free Full-Text
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Monthly improvements in paid work productivity: ankylosing spondylitis
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Recommendations for the management and treatment of ankylosing spondylitis – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open science hub.
Recomendado para você
você pode gostar

© 2014-2024 jeart-turkiye.com. All rights reserved.